Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable
Executive Summary
Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.
You may also be interested in...
Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely
Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.
Happy Holidays: ‘Most Favored Nation’ Rule Effective Date Likely To Be Delayed
Either through the courts or a postponement by the Trump administration itself, the Medicare Part B rule seems destined to remain dormant instead of going into effect in January as scheduled.
Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.